The discovery of novel melatonin receptor molecules may make possible therapies for such circadian rhythm disburbances as jet lag, shift work, depression and sleep disorders.
The $21.7 million Clinical and Translational Science Award recognizes UB’s progress in bringing the benefits of clinical and translational science to patients.